Ojjaara

Active Ingredient(s): Momelotinib Dihydrochloride
FDA Approved: * September 15, 2023
Pharm Company: * GLAXOSMITHKLINE LLC
Category: Cancer
* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Ojjaara 200 mg Oral Tablet
NDC: 81864-101
Labeler:
Glaxosmithkline LLC
Ojjaara 150 mg Oral Tablet
NDC: 81864-102
Labeler:
Glaxosmithkline LLC
Ojjaara 100 mg Oral Tablet
NDC: 81864-103
Labeler:
Glaxosmithkline LLC